BRAF and central nervous system cancer: Examination of the gene-targeted “Clinical Glioma” and “KIAA1549-BRAF fusion” panels revealed that 98.2% (112/114) of brain astrocytomas had at least one molecular alteration (mutation or fusion), while only 65% (36/55) of IMAs had at least one alteration (Fisher test: p < 10− 6, Table 3).